Korro Bio (KRRO)
NASDAQ:KRRO
Want to see KRRO full AI Analyst Report?
KRRO Stock Chart & Stats
$14.39
-$1.03(-2.68%)
At close: 4:00 PM EST
$14.39
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $55.89
Previous CloseN/A
Volume28.02K
Average Volume (3M)734.66K
Market Cap
$193.41M
Enterprise Value$114.66M
Total Cash (Recent Filing)$113.97M
Total Debt (Recent Filing)$42.88M
Price to Earnings (P/E)―
Beta2.68
Next Earnings
Aug 18, 2026EPS Estimate
-1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.68
Shares Outstanding14,422,571
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue29.84
Enterprise Value/Gross Profit40.76
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$19.70Price Target Upside36.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-5.32
Revenue Forecast (FY)$1.68M
Bulls Say, Bears Say
Bulls Say
Pipeline: KRRO-111 AdvancementSelection of KRRO-111 with >90% editing and ~90% functional protein restoration in preclinical PiZZ models materially strengthens Korro's therapeutic pipeline. This durable program-level progress validates the RNA editing platform, raises probability of future value-inflecting clinical milestones and supports longer-term licensing or partnership optionality.
Capital Runway From $85M PIPEAn oversubscribed $85M PIPE that management says extends runway into 2H 2028 materially reduces near-term liquidity risk. This durable capital buffer enables multi-program clinical advancement, limits emergency financings, and gives management time to progress trials and pursue non-dilutive partnerships or milestone revenue.
Manageable Leverage And Balance-sheet CapacityMeasured leverage (TTM debt-to-equity ~0.36) and meaningful assets provide balance-sheet capacity to fund near-term R&D. This structural financial flexibility supports continued program investment and strategic transactions without immediately impairing solvency, improving the company's ability to absorb development risk over the medium term.
Bears Say
High Cash BurnSustained negative operating and free cash flow near -$70M TTM creates an ongoing funding requirement. Over 2–6 months this structural burn rate necessitates continued capital raises or partnering, raising dilution risk and constraining strategic optionality if clinical or partnership milestones slip or revenues do not scale.
Small, Declining Revenue BaseA tiny and falling revenue base (~$3.8M TTM, down ~40%) signals limited commercial or licensing income to offset R&D spend. This persistent revenue volatility reduces visibility on sustainable cash inflows and increases dependence on equity financings and milestone payments, undermining long-term self-sufficiency.
Persistent Large Operating And Net LossesConsistent, sizable operating and net losses reflect a cost base far exceeding revenues and negative returns. Structurally weak profitability increases the probability of dilution, continued external financing, and limits margin improvement until meaningful commercial revenues or high-value partnerships materialize.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $193.41M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is Aug 18, 2026 which is in 76 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on May 07, 2026. The company reported -$1.69 earnings per share for the quarter, beating the consensus estimate of -$1.727 by $0.037.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -1.31.
How many shares outstanding does Korro Bio have?
Korro Bio has 14,422,571 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$1.69 in its last earnings report, beating expectations of -$1.727. Following the earnings report the stock price went down -3.373%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.70 (36.90% Upside)
$19.70 (36.90% Upside)
Hedge Fund Trend
Increased
By 409.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-88.72%
12-Months-Change
Fundamentals
Return on Equity
-117.86%
Trailing 12-Months
Asset Growth
-9.19%
Trailing 12-Months
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
KRRO Stock 12 Month Forecast
Average Price Target
$19.70
▲(36.90% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―